

FAMILY

Running in the FAMILY – Understanding and predicting the intergenerational transmission of mental illness

Prof. Bjørn H. Ebdrup

- Professor and Consultant Psychiatrist
- Leader of Centre for Neuropsychiatric Schizophrenia Research, CNSR
- Mental Health Centre Glostrup | University of Copenhagen
- Faculty of Health and Medical Sciences | Department of Clinical Medicine | Denmark





COPSYCH – 10 year follow up

Open access

Protocol

BMJ Open Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial - the COPSYCH study protocol

> Parisa Mohammadzadeh ⁽ⁱ⁾, ^{1,2} Julie Bøjstrup Rosenberg ⁽ⁱ⁾, ^{1,2} Rebecca Vinding, ² Jens Richardt Møllegaard Jepsen, ¹ Ulrich Lindberg, ³ Nilo Følsgaard, ² Mikkel Erlang Sørensen, ¹ Daban Sulaiman, ^{1,3} Niels Bilenberg, ^{4,5} Jayachandra Mitta Raghava, ^{1,3} Birgitte Fagerlund, ^{1,6} Mark Vestergaard, ³ Christos Pantelis, ^{1,7} Jakob Stokholm, ² Bo Chawes, ² Henrik Larsson, ^{3,8} Birte Yding Glenthøj, ^{1,8} Klaus Bønnelykke, ² Bjørn H Ebdrup, ^{1,8} Hans Bisgaard²

FAMILY

BM

Mohammadzadeh P, et al. BMJ Open 2022;12:e047706. doi:10.1136/bmjopen-2020-047706







COPENHAGEN PROSPECTIVE STUDIES ON ASTHMA IN CHILDHOOD Prof Klaus Bønnelykke



Centre for Neuropsychiatric Schizophrenia Research, CNSR Prof Bjørn H Ebdrup



https://copsac.com/home/research-clusters/copsych/





Team COPSYCH





Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.



Funded by the European Union





The COPSAC2010 cohort











- Supplement during pregnancy from pregnancy week 24:
 - N-3 LCPUFA (fishoil), 2.4g/dag (55% EPA and 37% DHA) vs oliveoil
 - Vitamin D (2,400 IU/dag ~ 60 mikrogram/dag) vs placebo

<u>Group 1</u>	<u>Group 2</u>	Group 3	<u>Group 4</u>	
Vitamin D	Vitamin D	Placebo	Placebo	
Fishoil~LPUFA	Placebo	Fishoil~LPUFA	Placebo	







Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.




Funded by the European Union



Primary endpoint: Development of persistent wheeze/asthma





- Fish oil supplementation: 2,4 g/day
- Unchanged after adjustment for gender, vitamin-D supplementation and women's blood level of EPA+DHA


December 29, 2016 N Engl J Med 2016; 375:2530-2539 DOI: 10.1056/NEJMoa1503734







The COPSAC2010 cohort



Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.




Funded by the European Union









Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.




Funded by the European Union














Clinical follow-up




Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.

Funded by the European Union








Funded by the European Union, the Swiss State Secretariat for Education, Research and Innovation (SERI) and the UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee". Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.

Fu the



Previous neurodevelopmental findings






Figure 2. Effect of the n-3 LCPUFA pregnancy supplementation on age of milestone achievement for boys and girls. The effect is illustrated as the difference (in days) in milestone achievement, using the control group as the reference.

Significant difference is indicated with asterisk (*) and p-value.

Figure3:

The effect of n-3 LCPUFA intervention in pregnancy on composite score of the Bayley cognitive test at age 2 $\frac{1}{2}$ years among boys.

Sass et al., Child Dev 2021

Funded by the European Union, the Striss State Septeration (UKRI) under the UK government's Horizon Europe funding guarantee'. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union, or the European Health and Digital Executive Agency (HADEA), the SERI or the UK Research and Innovation (UKRI). Neither the European Union nor the granting authorities can be held responsible for them.








COPSYCH 10-year visit

- 2-day visit
 - Clinical visit, COPSAC
 - MRI brain scanning, Glostrup







Cognition ~ 2.5 hours incl. small breaks

- Executive Functions
- Verbal memory
- Attention and reaction time
- Processing speed
- Fine motor skills
- Intelligence

TOF









Psychopathology ~ 2 hours

Parent – 45 min

- Clinical interviews:
 K-SADS-PL
- ADHD-RS
- Strengths and difficulties
- Social Responsiveness Scale-2
- Child Behavior Checklist
- BRIEF-2 on Executive Functions




 Clinical interviews: K-SADS-PL

Psychosis Supplement

Magical thinking questionnaire







Survey scan + Head coil ref. scan

T1W 3D high resolution

3:00 min 4:00 min 10:00 min

Total scanning time

Q-flow (total CBF)

MR Spectroscopy

DTI (30 dir)

MTR

T1

39:13 min ~ 1 hour




1:15 min









Funded by the European Union








COPSAC visits: 604 participated in the COPSYCH-visit
 86 % of the original cohort

MR scans: 489 completed visits
 70 % of entire cohort
 (61 MRI scans excluded ---- 428 MRI scans after QC)











Neurocognitive test battery

Table 1 Neurocognitive test battery				
Neurocognitive domain	Test	Outcome variable		
Speed of processing	Coding (WISC-IV)*	Total number correct.		
	Symbol search (WISC-IV)	Sum of total number correct, errors subtracted.		
	Trail making test 2-number sequencing (D-KEFS)†	Time to complete in seconds.		
Attention/vigilance	Rapid visual information processing (CANTAB)‡	A' (A prime).**		
	Reaction time (CANTAB)	Simple and five-choice reaction time.		
Motor functioning	Reaction time (CANTAB)	Simple and five-choice movement time.		
Fine motor dexterity	Grooved pegboard	Time to complete for the dominant and non-dominant hand.		
Verbal memory	Word selective reminding-immediate recall (TOMAL-2)§	Total number of words recalled over six learning trials.		
	Object recall (TOMAL-2)	Total number of objects recalled over five learning trials.		
Verbal working memory	Digit span (WISC-IV)	Total number of correcr forward and backward digit sequencing.		
	Letter-number sequencing (WISC-IV)	Total number of correct sequences.		
Visual memory	Paired associates learning (CANTAB)	First trial memory score, total errors (adjusted).		
Executive functions				
Flexibility/set shift	Intra-extra dimensional set shift (CANTAB)	Extra-dimensional stage errors. ++		
	Trail making test 4-number-letter switching (D-KEFS)	Time to complete in seconds.		
Spatial working memory	Spatial span task (CANTAB)	Span length.##		
	Spatial working memory (CANTAB)	Total errors§§ and strategy formation.		
Planning	Stockings of cambridge (CANTAB)	Problems solved in minimum moves.		
Behaviour rating of executive functions	BRIEF-2¶	Impulse control, self-monitoring, flexibility, emotional control, initiating, planning/organisation, working memory and task monitoring.		
Intelligence	Vocabulary (WISC-IV)	Total number correct.		
	Matrices (WISC-IV)	Total number correct.		

